Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEGA THERAPEUTICS, INC.

(OMGA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omega Therapeutics : Goldman Sachs Starts Omega Therapeutics at Neutral With $22 Price Target

08/24/2021 | 07:18am EST


ę MT Newswires 2021
All news about OMEGA THERAPEUTICS, INC.
11/18Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare C..
PR
11/10Omega Therapeutics Narrows Loss in Q3
MT
11/10Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corpor..
PU
11/10OMEGA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/10Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corpor..
PR
11/09Omega Therapeutics to Present at the Jefferies London Healthcare Conference
PR
11/08OMEGA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
10/14OMEGA THERAPEUTICS : Working With Stanford University to Explore Use of Omega Epigenomic C..
MT
10/14OMEGA THERAPEUTICS : Announces Strategic Research Collaboration with Stanford University S..
PR
10/14Omega Therapeutics, Inc. Announces Strategic Research Collaboration with Stanford Unive..
CI
More news
Analyst Recommendations on OMEGA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -71,6 M - -
Net cash 2021 209 M - -
P/E ratio 2021 -6,30x
Yield 2021 -
Capitalization 808 M 808 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees -
Free-Float 96,3%
Chart OMEGA THERAPEUTICS, INC.
Duration : Period :
Omega Therapeutics, Inc. Technical Analysis Chart | OMGA | US68217N1054 | MarketScreener
Technical analysis trends OMEGA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 16,91 $
Average target price 29,50 $
Spread / Average Target 74,5%
EPS Revisions
Managers and Directors
Mahesh Karande President, Chief Executive Officer & Director
Roger A. Sawhney Chief Financial Officer
Noubar B. Afeyan Chairman
Thomas McCauley Chief Scientific Officer
Mary T. Szela Director
Sector and Competitors
1st jan.Capi. (M$)
OMEGA THERAPEUTICS, INC.0.00%808
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431